For the Quarter Ending December 2025
North America
• In the USA, the Rifaximin Price Index rose by 5.86% quarter-over-quarter, reflecting higher landed costs from China.
• The average Rifaximin price for the quarter was approximately USD 279185.00/MT per CFR Los Angeles.
• Rifaximin Spot Price firmed on controlled exports and steady shipments into West Coast distribution networks.
• Rifaximin Price Forecast indicates gradual modest increases as buyers advance orders ahead of reimbursement adjustments.
• Rifaximin Production Cost Trend showed stability overall, with localized cost pressure from Chinese manufacturing disruptions.
• Rifaximin Demand Outlook remained resilient owing to steady prescriptions and brand-driven offtake supporting firm offers.
• Rifaximin Price Index benefited from supplier offers and limited spot discounting despite softer freight costs.
• Inventory and export demand balanced availability, while port operations normalized, sustaining narrow upward price momentum.
Why did the price of Rifaximin change in December 2025 in North America?
• Buyers' advanced orders anticipating reimbursement changes, allowing exporters to pass a modest premium onto CFR invoices.
• Stable supply from Italy and India, declining freight rates, yet sellers maintained firm contract offers.
• Consistent prescription demand and brand exclusivity reduced discounting, supporting price firmness despite flat production economics.
APAC
• In China, the Rifaximin Price Index rose by 5.87% quarter-over-quarter, driven by export strength globally.
• The average Rifaximin price for the quarter was approximately USD 279100.00/MT, supporting measured seller discipline.
• Rifaximin Spot Price firmed modestly as Shanghai free-trade warehouses kept moderate stocks and steady shipments.
• Rifaximin Production Cost Trend rose as rifamycin SV import costs and euro strength pressured converters.
• Rifaximin Demand Outlook stayed constructive as hospital tenders and international buyers maintained disciplined restocking schedules.
• Rifaximin Price Forecast suggests a mild upward trajectory as exporters hold firm offers amid steady offtake.
• Rifaximin Price Index movements were muted by balanced inventories and normalized reefer freight on lanes.
• Zhejiang and Jiangsu plants operated near capacity, preserving export volumes while avoiding environmental compliance-related shutdowns.
Why did the price of Rifaximin change in December 2025 in APAC?
• Export call-offs from India and Brazil increased in December, tightening availability despite steady domestic output.
• Firmer rifamycin SV feedstock and stronger euro raised conversion costs, leading producers lift FOB offers.
• Shanghai port normalization and steady reefer freight avoided bottlenecks, allowing increased loading and timely shipments.
Europe
• In Germany, the Rifaximin Price Index rose by 5.85% quarter-over-quarter, driven by Chinese production costs.
• The average Rifaximin price for the quarter was approximately USD 279173.33/MT, reflecting Hamburg landed costs.
• Rifaximin Spot Price liquidity was thin, while the Price Index firmed on imports and restocking.
• Rifaximin Price Forecast shows gains as Rifaximin Production Cost Trend sustains upward pressure from intermediates.
• Rifaximin Demand Outlook remains positive, supporting the Price Index as prescriptions and distributor offtake grow.
• Rifaximin Price Index sensitivity to currency and logistics compelled importers to absorb costs, constraining pass-through.
• Major origins Italy, India, and China operated normally, exporters adjusted offers reflecting marginally tighter inventories.
• Forward buying supported moderate gains; Rifaximin Price Forecast and Spot Price outlook suggest gradual firming.
Why did the price of Rifaximin change in December 2025 in Europe?
• Elevated Asian production costs increased FOB levels, transmitting higher landed costs into Germany's import market.
• Logistics friction and handling premiums at Hamburg lengthened lead times and increased CFR landed-price components.
• Solid prescription demand and distributor restocking, constrained by rebate rules, supported steady offtake without pass-through.
For the Quarter Ending September 2025
North America
• In USA, the Rifaximin Price Index rose by 0.08% quarter-over-quarter, reflecting marginal forward buying activity.
• The average Rifaximin price for the quarter was approximately USD 263728.33/MT, based on invoiced imports.
• Rifaximin Spot Price remained subdued with stable supply, keeping the Rifaximin Price Index largely flat.
• Rifaximin Price Forecast indicates upward bias as Rifaximin Production Cost Trend sees persistent inflationary pressure.
• Rifaximin Demand Outlook points to steady healthcare offtake supporting the Price Index through seasonal cycles.
• Inventory buffers drawn earlier limited urgent imports, reducing pressure on the Rifaximin Price Index short-term.
• Major supplier operational continuity maintained, while freight volatility influenced Rifaximin Production Cost Trend and costs.
• Market participants adopt cautious buying; Rifaximin Price Forecast expects controlled rises amid measured replenishment activity.
Why did the price of Rifaximin change in September 2025 in North America?
• Precautionary forward buying amid tariff uncertainty temporarily increased inbound demand, nudging prices slightly upward recently.
• Elevated inventories from earlier strategic imports reduced replenishment urgency, placing downward pressure on spot Price Index.
• Logistics stability with minor port delays increased landed costs modestly, influencing near-term Price Index movement.
APAC
• In China, the Rifaximin Price Index rose by 0.10% quarter-over-quarter, supported by stable export interest.
• The average Rifaximin price for the quarter was approximately USD 263633.33/MT, reflecting balanced market conditions.
• Producers reported manageable inventories and balanced shipments, keeping the Rifaximin Spot Price stable through September.
• Outlook indicates modest upside as the Rifaximin Price Forecast factors steady demand and holiday logistics.
• Freight and raw material shifts altered the Rifaximin Production Cost Trend, applying upward pressure overall.
• Global procurement pauses and domestic restocking shaped the Rifaximin Demand Outlook, leaving volumes steady, cautious.
• Export variability and occasional sailing cancellations affected distribution and reflected in the Rifaximin Price Index.
• Manufacturers sustained production alignment with orders, avoiding overstocking while maintaining offers and margin stability overall.
Why did the price of Rifaximin change in September 2025 in APAC?
• Mild export restocking and steady domestic procurement increased demand slightly, supporting marginal net price gains.
• Container freight cost increases added logistical expense, prompting suppliers to pass through limited cost recoveries.
• Domestic manufacturing stability prevented oversupply despite softer external orders, balancing market and preventing larger declines.
Europe
• In Germany, the Rifaximin Price Index rose by 0.10% quarter-over-quarter, in Q3 2025, reflecting logistical stability and procurement restraint.
• The average Rifaximin price for the quarter was approximately USD 263740.00/MT, based on reported CFR Hamburg shipments.
• Rifaximin Spot Price remained muted, and the Rifaximin Price Index showed minimal upward pressure amid cautious buying.
• Rifaximin Price Forecast indicates marginal gains through Q4 as logistics normalize and selective forward buying supports modest firmness.
• Rifaximin Production Cost Trend remained steady with limited feedstock or manufacturing cost escalation influencing list prices modestly.
• Rifaximin Demand Outlook stays stable; hospitals and pharmacies maintain short-cycle orders, avoiding speculative bulk procurement.
• Inventory buffers across German warehouses dampened volatility while export demand remained limited, keeping spot offers subdued.
• Major producer maintenance and selective Chinese offloads influenced offers, while port congestion adjustments limited shipment frequency.
Why did the price of Rifaximin change in September 2025 in Europe?
• Moderate port congestion delayed shipments slightly, creating mild supply timing issues without substantial shortages overall.
• Freight schedule variability and carrier re-routing increased logistical costs, prompting cautious procurement and timing adjustments.
• Adequate inventories and restrained forward buying prevented sharp price moves despite shipping and geopolitical risks.
For the Quarter Ending June 2025
North America
• The Rifaximin Price Index in the USA declined by 0.81% in April, followed by marginal gains of 0.20% in May and 0.07% in June, with spot prices moving from USD 263,100/MT in April to USD 263,807/MT in June.
• In April, product spot price weakened as downstream buyers reduced orders due to high inventories, and suppliers cut prices to clear stock.
• Elevated tariffs (145%) on Chinese imports prompted pre-shipment strategies that created excess stock, suppressing demand and weighing down the price index.
• The April product demand outlook was bearish, with buyers pausing new orders amid tariff uncertainty and high inventories.
• May saw a minor rebound as the 90-day tariff suspension encouraged cautious forward-buying, contributing to upward movement in the product spot price.
• Rising freight costs, peak season surcharges, and equipment shortages in May supported a modest increase in the product price forecast.
• In June, Rifaximin prices stayed relatively flat; market stability reflected balanced supply and moderate forward purchasing.
• Ongoing U.S.–China policy concerns in June led some buyers to mildly frontload, anticipating Q3 logistics disruptions.
• Domestic demand remained stable across all Q2 months, especially in the GI and infectious disease segments.
• For July 2025, the product price forecast leans toward an increase, driven by expected port congestion, delayed shipments, and cautious procurement behavior.
APAC
• The Rifaximin Price Index in China fell by 0.77% in April, followed by a marginal uptick of 0.19% in May and 0.05% in June. This reflects a near-stable quarter shaped by subdued demand and moderate supply conditions.
• In April, the product spot price dropped due to weak international demand, mounting backlogs, and export hurdles stemming from 145% U.S. tariffs, which sharply impacted Chinese pharmaceutical competitiveness.
• Ongoing inventory overhangs and order cancellations from the U.S. led suppliers to offer aggressive discounts, driving down prices despite adequate availability—highlighting a negative product demand outlook at the start of Q2.
• China’s manufacturing contraction in April (PMI at 49.0) worsened port congestion and disrupted logistics, further reducing seller flexibility and dampening Rifaximin’s price index.
• In May, product spot prices rebounded slightly to RMB 263,500/MT as freight disruptions persisted, but steady production post-Labour Day holidays and firm inventory coverage kept prices largely stable.
• Temporary suspension of U.S. tariffs led to modest export interest; some U.S. buyers resumed procurement to rebuild stocks, creating a neutral product demand outlook without prompting a sharp shift in prices.
• By June, the price index rose marginally amid forward ordering by international clients and manageable supply levels, while logistics-related freight increases nudged exporters to adjust prices modestly.
• June saw steady production cost trends with no major imbalances, as Chinese manufacturers aligned output to demand, maintaining calm market dynamics through the end of Q2.
• For July 2025, prices are likely to increase slightly, supported by steady domestic buying from formulation units, moderate overseas demand, and continued stability in manufacturing and logistics.
• The product price forecast suggests that manageable inventories and stable factory operations will maintain supply-side discipline, while forward ordering and regular restocking offer modest price support.
Europe
• The Rifaximin Price Index in Germany declined by 0.77% in April 2025, reaching USD 263,087/MT, pressured by oversupply caused by US tariff redirections and subdued domestic demand.
• Product spot price dropped sharply in April due to increased volumes redirected from the US to Germany and pre-stocking ahead of the May holidays, leaving buyers with surplus inventories.
• Product demand outlook remained weak in April as buyers held off purchases amid congestion at ports like Hamburg and Rotterdam, while pharma procurement activity stayed flat.
• In May 2025, the Price Index rose marginally by 0.19% to USD 263,590/MT, reflecting a balance between stable demand and rising shipping constraints across Northern Europe.
• Although port congestion and Rhine water-level issues extended lead times in May, pre-booked shipments kept inventory levels adequate and stabilized product spot price movements.
For the Quarter Ending March 2025
North America
Rifaximin prices in the U.S. remained relatively stable in Q1 2025, despite varying market pressures. In January, anticipated 10% tariffs on Chinese goods led importers to accelerate shipments, temporarily increasing demand. However, effective supply chain planning and manageable port delays from California wildfires kept prices steady.
In February, prices declined due to improved Chinese output post-holidays, soft domestic demand, and reduced shipping costs. Buyers showed restraint amid economic uncertainty, inflation concerns, and potential tariff risks on Chinese and Indian pharmaceuticals. Many had already restocked in January, dampening February’s purchasing activity.
By March, prices edged higher as buyers ramped up procurement ahead of new trade barriers. The imposition of further tariffs on China and other key partners by former President Trump on March 4 spurred anticipatory buying. Slightly easing inflation and improved sentiment also contributed to firmer demand.
Overall, Q1 was marked by cautious procurement, geopolitical tensions, and fluctuating demand, with price movement kept largely in check through effective supply chain adaptation and forward purchasing strategies.
Asia Pacific
In Q1 2025, Rifaximin prices in China experienced a modest upward trend driven by persistent supply constraints and steady demand from the pharmaceutical and healthcare sectors. January saw a slight price increase due to reduced manufacturing activity ahead of the Lunar New Year, combined with pre-holiday bulk orders and exporters rushing shipments before impending U.S. tariffs. In February, production delays extended due to the prolonged holidays, while steady foreign demand—particularly from European buyers amid trade tensions with the U.S.—intensified pressure on limited inventories. Prices continued to rise marginally in March as output gradually improved but remained insufficient to match the strong demand. Domestic consumption was supported by fiscal stimulus and restocking efforts ahead of scheduled plant maintenance, while foreign buyers accelerated procurement in anticipation of further trade restrictions. Throughout the quarter, market sentiment stayed firm, with suppliers maintaining upward pricing strategies amid tight availability. Overall, the quarter was marked by a delicate supply-demand imbalance, geopolitical trade uncertainty, and cautious restocking that sustained moderate price increases.
Europe
In Q1 2025, the Rifaximin market in Germany displayed notable price fluctuations influenced by shifting economic sentiment, supply chain dynamics, and downstream demand trends. January saw a moderate price increase as improved business morale, early inventory restocking, and pre-Lunar New Year demand from Asia bolstered procurement activity. The pharmaceutical and healthcare sectors, anticipating steady demand, contributed to firm buying interest. However, in February, prices declined due to ample supply from earlier stockpiling, weakened consumer sentiment amid political uncertainty, and favorable import conditions—including reduced freight costs and a stronger Euro—leading to subdued demand and increased competition among sellers. In March, prices rose again, supported by tightening supply conditions linked to port congestion and labor unrest in Europe. Renewed restocking efforts and more confident buying behavior—partly due to a marginal decline in Eurozone inflation—boosted demand from downstream sectors. Overall, Q1 was characterized by alternating phases of robust restocking and cautious procurement, shaped by a complex interplay of economic optimism, logistical challenges, and evolving pharmaceutical demand.
